Close

bluebird bio (BLUE) to Present New Data from LentiGlobin Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease Clinical Studies at EHA

May 17, 2018 9:08 AM EDT Send to a Friend
bluebird bio, Inc. (Nasdaq: BLUE) announced that data from ongoing LentiGlobin clinical studies in transfusion-dependent β-thalassemia (TDT) and severe sickle ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login